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Introduction: Understanding variability in the response to asthma medica-
tions is essential to ensure appropriate prescribing. Given that there are
increased asthma treatment failures observed in ethnic minorities receiving
asthma therapeutics, it is fundamental to understand the factors related to
ethnicity that can modify the response to asthma therapy.
Areas covered: Race/ethnicity is an important determinant of drug response
and therefore contributes to interindividual variability. It is generally recog-
nized that its effects on drug response are determined by both genetic and
environmental factors to a varying extent, depending on the ethnic groups
and probe drugs studied. Also, adherence to therapy can influence pharmaco-
logical response to asthma therapeutics.
Expert opinion: Health-care professionals might never use the treatment in
their patients irrespective of their ethnicity and thus inadvertently increase
ethnic health inequality. However, our understanding of whether and/or
how ethnicity influences pharmacological response to asthma therapeutics is
still very scarce. A holistic, integrative systems biology approach that
combines large-scale molecular profiling traits (e.g., transcriptomic,
proteomic, metabolomic traits) and genetic variants could help to personalize
the treatment of asthmatic patients regardless of race/ethnicity.
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1. Introduction
Race distinguishes major groups of people according to their ancestry and a more or
less distinctive combination of physical characteristics. On the contrary, according
to the Oxford Dictionaries, ethnicity is the fact or state of belonging to a social
group that has a common national or cultural tradition [1]. This means that culture,
religion, ancestry and language should be incorporated in the concept of ethnicity.
Consequently, ethnicity not only includes what is usually called race, but also refers
to characteristics that are of social, psychological, cultural and political nature [2].
Ethnic disparities in health and health care recently have received considerable
attention. The quality of health care received by ethnic minority groups has overall
been shown to be poorer than that received by the majority population and this is
likely to contribute to their poorer health outcomes [3]. There are multiple factors
associated with ethnic disparities in health and health care. These factors include
structural barriers (e.g., ability to access the health-care system), process-of-care
barriers (e.g., ability to navigate the health-care system), and process-of-care barriers
at the interpersonal level (e.g., ability to work effectively with a health-care provider)
for equitable, quality care [4].
However, several key issues were identified as likely to be ethnic-specific rather
than a reflection of minority status: impact of parental and professional knowledge
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and beliefs, health service utilization pattern explanations and
the impact of prejudice and stigmatization [5].
As elegantly highlighted by Davidson et al. [3], ethnic
minority asthma sufferers are less well managed by specialist
and preventative care, less likely to be prescribed guidance-
based treatments, and are more likely to leave consultations
without care plans or appropriate prescription. All this in
itself makes the quality of asthma treatment poor. However,
an analysis that compared African Americans and whites
who participated in clinical trials, and thus had equal access
to asthma caregivers and asthma medications, documented
that African Americans experienced a higher rate of asthma
treatment failures than whites [6]. The increased rate of treat-
ment failures seemed to occur in African Americans being
treated with long-acting b2-agonists (LABAs), without a
protective effect by the concomitant use of either inhaled cor-
ticosteroids (ICSs) or leukotriene receptor antagonists
(LTRAs). Moreover, a Danish study that analyzed data
obtained from the Danish Civil Registration System, the Cen-
tral Taxpayers’ Register and the Danish National Prescription
Register documented that in Denmark ethnic differences in
the use of anti-asthmatic medication are present to a higher
degree for preventive rather than relief medication and this
can induce a higher risk of under-medication and suboptimal
disease control [7]. These differences cannot be explained by
socioeconomic characteristics because they have been
recorded within a Nordic welfare context where access to
health-care services is free with no payment, and with outpa-
tient prescription drug use being highly reimbursed for
chronic conditions.
Since, a possible explanation for the increased asthma treat-
ment failures observed in ethnic minorities receiving asthma
therapeutics is that some minorities might have a pharmaco-
genomic predisposition to either nonresponse or to adverse
response with this class of therapy [8], it is fundamental to
understand, when possible, the factors related to ethnicity
that can modify the response to asthma therapy. In assessing
the role of ethnicity on response to asthma therapeutics both
genetic and environmental factors must be considered.
Epidemiologic trends suggest that asthma may provide an
excellent paradigm for understanding the role of ethnicity
on health disparities. Ethnicity is an important determinant
of drug response and therefore contributes to interindividual
variability. It is generally recognized that the effects of ethnic-
ity on drug response are determined by both genetic and envi-
ronmental factors to a varying extent, depending on the ethnic
groups and probe drugs studied [9]. Also adherence to therapy
can influence pharmacological response to asthma
therapeutics.
Since understanding variability in the response to asthma
medications is essential in order to ensure appropriate pre-
scribing, in this review we will describe the influence of eth-
nicity on pharmacological response to asthma therapeutics.
2. Genetic factors
Several genetic factors that affect the pharmacotherapeutic
responses to asthma medications have now been recognized.
2.1 b2-agonists
Pharmacogenetic studies in multiethnic populations have
focused on the gene encoding for the b2-adrenoceptor
(ADRB2), which is located on chromosome 5q31 -- 33. So
far, nearly 49 validated genetic polymorphisms in the ADRB2
gene have been described, with the greatest attention devoted
to the single-nucleotide polymorphisms (SNPs) causing amino
acid substitutions at positions 16 and 27. Several SNPs have
been identified in the coding region of the ADRB2 gene [10].
The most common SNPs result from three missense mutations
in the coding region of ADRB2. The first SNP (A>G), at nucle-
otide 46, causes the substitution of glycine (Gly) for arginine
(Arg) at codon 16, while the second one (C>G), at nucleotide
79, results in the substitution of glutamic (Glu) acid for gluta-
mine (Gln) at codon 27 and the third one the substitution of
isoleucine (Ile) for threonine (Thr) at codon 164 [10]. Replace-
ment of the base may not only alter the gene expression and
function of the b2-adrenoceptor, it may also alter the response
to b2-agonist therapies.
Article highlights.
. A possible explanation for the increased asthma
treatment failures observed in ethnic minorities receiving
asthma therapeutics is that some minorities might have
a pharmacogenomic predisposition to either
nonresponse or to adverse response with this class of
therapy.
. The effects of ethnicity on pharmacological response to
asthma therapeutics are also determined by
environmental factors to a varying extent, depending on
the ethnic groups.
. Differences in adherence to therapy by race-ethnicity are
well described. Adherence to therapy can influence
pharmacological response to asthma therapeutics.
. The published evidence clearly shows that our
understanding of whether and/or how ethnicity
influences pharmacological response to asthma
therapeutics is still very scarce and almost all the
information available to us have been produced in the
United States.
. Minority ethnic people are markedly under-represented
in research.
. Studying response to specific therapies using race as a
phenotype is a too simplistic approach and could lead to
erroneous conclusions because it does not reflect the
complexity of asthma.
. A personalized approach based on individual
characteristics such as age, body mass index, race, and
local environment, with incorporation of predictive
biomarkers including genetic profiles or scores that
combine several risk-associated genetic variants is
needed.
This box summarizes key points contained in the article.
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The Arg16Gly and Gln27Glu polymorphisms result in dif-
ferential agonist-stimulated b2-adrenoceptor downregulation
in transfected cell systems, including human airway smooth
muscle cells [11]. Significantly greater isoprenaline-induced
b2-adrenoceptor downregulation was demonstrated in recep-
tors with the Gly16 compared with the Arg16 genotype [11].
Conversely, the Glu27 allele is relatively resistant to downre-
gulation of b2-adrenoceptor during exposure to b2-agonists
in comparison with receptors with the Gln27 genotype [11].
When Glu27 is co-inherited with Gly16, phenotypic
responses favor the Gly16 genotype [11]. Gln27 influences
the behavior of cells with the Gly16Gln27 haplotype, which
exhibits less acute and long-term desensitization as measured
by cAMP levels [11]. The Thr164Ile polymorphism has been
associated with impaired receptor ligand binding and cou-
pling to Gs protein in response to different short-acting
b2-agonists (SABAs) such as isoproterenol and salbutamol
resulting in a significant reduction in basal b2-adrenoceptor
activity and agonist-stimulated activation, at least in vitro [11].
In initial clinical studies that examined the influence of
b2-adrenoceptor genotype on the response to long-term and
repeated dosages of SABAs, the Arg16 genotype was more
closely associated with reduced responses with enhanced
agonist-mediated desensitization than Gly16 genotype [10],
but subsequent studies found opposite results or no associa-
tion [12]. Also the evidence regarding the association between
ADRB2 polymorphism and altered response to LABAs is
rather inconsistent [10,11]. Two prospective genotype-stratified
trials, the Asthma Clinical Research Network Long-Acting
Beta Agonist Response by Genotype (LARGE) Trial [13] and
a trial by Bleecker et al. [14] failed to show differences in
peak expiratory flow rate (PEFR) responses between
Gly16Arg genotypes during LABA treatment, independent
of whether LABA was administered as a monotherapy or in
combination with ICS therapy. However, in the LARGE
trial [13], African--American subjects harboring the Arg/Arg
polymorphism demonstrated no incremental benefit of
LABAs with respect to lung function compared with placebo,
whereas Gly/Gly African Americans did improve with LABAs.
Genetic variation in ADRB2 differs significantly between
ethnic groups [15]. The allelic frequency of Arg16 is lower in
white Americans (39.3%) than in African Americans
(49.2%), and thus African Americans are more likely to be
homozygous for Arg16 (i.e., to have the Arg/Arg genotype)
[16]. Despite having more severe asthma, Puerto Ricans, who
are an admixed population of African, European, and Native
American ancestries, have lower bronchodilator response
compared with African Americans or Mexicans [17,18], and
African Americans have lower bronchodilator response com-
pared with patients of European ancestry [17,18]. Genetic varia-
tions may help to explain the lower response to salbutamol in
Puerto Ricans than other Hispanic subgroups [19].
However, we have already mentioned that the Arg/Arg
polymorphism at position 16 of the b-adrenoreceptor is also
present in African Americans and whites (allele frequency
0.5 in African Americans [20], 0.37 in a white Scottish popu-
lation [21]) and also in Han Chinese, Japanese and Mexican
Americans (allele frequency 0.58, 0.44 and 0.48, respec-
tively [22]). Therefore, it likely does not explain the whole
story regarding adverse effects of LABAs, and, in any case, it
is unlikely that these genetic variations account for the rare,
life-threatening events seen with LABA use [23]. Lastly, it has
been suggested that the rare ADRB2 variant Ile164 in non-
Hispanic white patients and an insertion--deletion polymor-
phism within the regulatory region (--376 In-Del) in African
Americans are associated with adverse events during LABA
therapy [24].
The results of a genome-wide association study suggested
that other rare variations contribute to individual differences
in response to salbutamol, notably in solute carrier genes
that include membrane transport proteins involved in the
transport of endogenous metabolites and xenobiotics [25]. It
is intriguing that a recent genome-wide association study of
bronchodilator response in patients of European ancestry
identified spermatogenesis associated, serine-rich 2-like
(SPATS2L) as a novel candidate gene for being an important
regulator of b2-adreneceptor downregulation [26]. The minor
allele of rs295137 in SPATS2L is associated with a greater
acute SABA bronchodilator response and is more common
in an African population compared with populations of Euro-
pean descent [26] and is less frequent in Han Chinese and
Japanese [22].
b-Agonists bind to b2-adreneceptor to activate a G-protein-
coupled receptor pathway via adenylyl cyclase type 9. An SNP
(Ile772Met) adjacent to adenylyl cyclase type 9 gene
(ADCY9) has been associated with salbutamol bronchodilator
response in Puerto Rican and Mexican asthmatics from the
Genetics in Latino Americans (GALA) study cohort [25].
ADCY9 has also been associated with bronchodilator response
to LABA in an ICS-treated Korean asthma cohort [27]. These
findings suggest that G-protein-coupled receptor pathway-
related gene variation might determine responsiveness to b-
agonists. The variable allele frequency between different
ancestral populations for ADCY9 is 0.36 in Americans with
European ancestry, 0.12 in Yorubans from Nigeria, 0.12 in
African Americans, 0.22 in Mexican Americans, 0.4 in Han
Chinese and 0.36 in Japanese [22]. The corticotrophin-
releasing hormone receptor-2 is a G-protein-coupled receptor
that regulates airway smooth muscle relaxation via adenylyl
cyclase activation Also an SNP adjacent to corticotrophin-
releasing hormone receptor-2 gene (CRHR2) has been associ-
ated with salbutamol bronchodilator response in Puerto Rican
and Mexican asthmatics [25].
2.2 Inhaled corticosteroids
Genetic variation could also contribute to significant
between-person variability in response to ICSs, although the
genetic predictors of a poor long-term response to ICS differ
markedly depending on the definition of response (exacerba-
tion versus improved lung function) [28]. Chan et al. found
Influence of ethnicity on response to asthma drugs
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that African Americans had a 38% prevalence of steroid-
resistant asthma compared with 12% in white patients [29].
An in vitro, study has suggested that steroid responsiveness
might differ between African American and white patients,
as evidenced by between-group differences in the ability of
dexamethasone to suppress T-cell proliferative responses [30].
Interethnic differences in steroid sensitivity reflect variation
in transcriptional response at many genes, including regula-
tors with large effects (e.g., NFKB1, a gene found to predict
lymphocyte steroid sensitivity within populations) and
numerous other genes with smaller effects [31]. Lower steroid
sensitivity in individuals of African ancestry reveals weaker
transcriptional response at a large number of genes [31].
Rosenwasser et al. [32] found an association between the
IL-4 C-589!T sequence variant in the IL4 gene promoter
polymorphism, which is linked with increased IL4 gene
transcription, and steroid-resistant asthma. Interestingly, the
frequency of this IL-4 C-589!T sequence variant is signifi-
cantly greater among African--American asthmatic patients
than among white asthmatic patients [33]. In any case, the
results of a study that sought to determine the degree to which
African--American patients respond to ICS medication and
whether the level of response is influenced by other factors,
including genetic ancestry suggested that genetic ancestry
might not contribute to differences in ICS controller response
among African--American patients with asthma [34].
Intriguingly, it has reported that in patients on ICS those
with the Arg16Arg genotype had a significantly lower metha-
choline PC20 than those with the Gly16Gly genotype, but
there was no interaction between ICS use and race (African
Americans and Whites with asthma) [35]. However, the
clinical response to an LABA did not differ among ADRB2
Arg16Gly SNPs during chronic dosing in the presence of an
ICS in Chinese Han asthmatic patients [36].
The minor allele of rs37972 in the glucocorticoid-induced
transcript gene GLCCl1 is associated with a diminished
response to ICSs and is less common in populations of
African descent compared with a European population [37].
2.3 Leukotriene modifiers
Cysteinyl leukotrienes (cysLTs) are synthesized from arachi-
donic acid located in membrane-phospholipids by cytosolic
phospholipase A2 in response to stimulation [38,39]. Arachi-
donic acid is converted to 5-hydroperoxyeicosatetraenoic
acid and leukotriene A4 (LTA4) by membrane-bound 5-lipox-
ygenase (ALOX5) and 5-lipoxygenase activating protein
(ALOX5AP). In human mast cells, basophils, eosinophils
and macrophages, LTA4 is converted to LTB4 by LTA4 hydro-
lase (LTA4H), or is conjugated with reduced glutathione by
LTC4 synthase to form LTC4. LTC4 is transported to the
extracellular space mainly by the multidrug resistance protein
1 (MRP1). LTC4 is converted to LTD4 and LTE4 by g-
glutamyltransferase and dipeptidase that promoter polymor-
phisms in the ALOX5 and the LTC4 synthase (LTC4S) genes
contribute to variability in response to LT modifiers and LT-
selective antagonists. The complexity of the LT pathway
explains why there are multiple pharmacogenetic loci in mod-
ulating the therapeutic response to leukotriene modifiers [39].
Variants in the ALOX5AP and LTA4H genes would modify
both the effects of leukotriene modifiers at the cysLT receptor
and the effects of LTB4 at its receptor, thereby affecting these
medications’ ability to augment bronchodilator responsive-
ness [40]. LTA4H and ALOX5AP polymorphisms are associ-
ated with augmentation of bronchodilator responsiveness by
leukotriene modifiers in Puerto Ricans, but not Mexicans [40].
The frequency of both LTA4H and ALOX5AP by racial
group is higher in Mexicans, Chinese and Japanese than in
African Americans, Africans living in Nigeria and European
white descents with ancestry from northern and Western
Europe [7].
Carrying two copies of a minor variant ALOX5 promoter
SP1 tandem repeat allele contributes to a trend toward worse
asthma control, likely because of an increased 5-lipoxygenase
activity [41]. Variant alleles for this tandem repeat polymor-
phism occur at a much higher frequency in African--American
children than in those of white European descent [41].
2.4 Theophylline
Theophylline is metabolized to 1,3-dimethyl uric acid
through 8-hydroxylation by CYP1A2, a subtype of CYP,
and partly by CYP2E1, as well as by CYP1A2, to 1-methyl-
xanthine through 3-demethylation or to 3-methylxanthine
through 1-demethylation [42]. Genetics appear to be responsi-
ble for ~ 35% of variability in CYP1A2 activity. The fre-
quency of poor metabolizer-phenotype status varies in
different racial/ethnic groups [43]. Examples of poor metabo-
lizer frequency in different populations are Australians (5%),
Chinese (5%) and Japanese (14%). Overall, Asian and
African populations have lower CYP1A2 activity compared
to Caucasians [44].
3. Exogenous or environmental factors
Environmental exposure to both allergens and air pollutants
exposures can influence not only the pathogenesis and severity
of asthma but also the response to therapy. Also obesity
increases susceptibility to asthma and can modify the response
to therapy.
3.1 Smoke
In subjects withmild asthma who smoke, the response to ICSs is
attenuated, suggesting that adjustments to standard therapy
may be required to attain asthma control [45]. Also secondhand
smoke induces a reduced response to corticosteroids [46].
There are several proposed mechanisms of corticosteroid
resistance in asthmatic smokers [47]. Cigarette smoking and
oxidative stress impair HDAC2 function [48]. HDAC activity
is necessary for corticosteroids to fully suppress cytokine
production. In fact, corticosteroids suppress multiple inflam-
matory genes that are activated in chronic inflammatory
M. Cazzola, et al.
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diseases by reversing histone acetylation of activated inflam-
matory genes through binding of liganded glucocorticoid
receptors to coactivator molecules and recruitment of
HDAC2 to the activated transcription complex. Moreover,
airway mucosal permeability is increased in smokers with nor-
mal lung function and in asthmatic patients who do not
smoke [47]. Another proposed mechanism of corticosteroid
resistance is the downregulation of b2-adrenoceptors in lym-
phocytes that is caused by cigarette smoking [47]. An increase
in the number of neutrophils found in the airway in heavy
smokers who have asthma has also been associated with
poor corticosteroid response [49].
A recent study that used the Centers for Disease Control
and Prevention’s 2009--2010 Behavioral Risk Factor Surveil-
lance System documented that both current and former
smokers had a significantly higher asthma prevalence than
nonsmokers among whites, blacks, Hispanics and American
Indians or Alaska Natives (current smokers only) but not
among Asian/Pacific Islanders and those in the other race cat-
egory [50]. Smoking behavior among adults varies with ethnic-
ity and secondhand smoke, with members of certain ethnic
groups (e.g., Puerto Ricans) smoking more often and/or
more heavily than members of other groups (e.g., Mexicans).
Interestingly, in a retrospective study, Chan et al. found that
patients with corticosteroid-insensitive asthma were more
likely to be African American [51]. Moreover, in a study that
showed that ICS use may be associated with augmented
bronchodilator responsiveness to salbutamol in Mexican
Americans and Puerto Ricans, but not in African Americans,
with persistent asthma, African--American asthmatic patients
had a higher prevalence of tobacco use than Mexican
Americans but not Puerto Ricans [52].
It must be mentioned that it has been reported the joint
effects of functional variants in ADRB2 and personal history
of smoking on asthma [53].
3.2 Obesity
Obesity is strongly associated with asthma [54]. This associa-
tion is stronger among women than men [55]. However, its
presence in black and Hispanic men supports the concept
that the male finding, while weaker, is indeed present among
some men [56] and ethnicity may play a role.
In effect, among asthmatics in the Childhood Asthma
Management Program (CAMP), the proportion of over-
weight was higher in blacks and Hispanics than in whites
and in members of other races [57]. In the United States,
21.2% in Mexican Americans, 24.3% in non-Hispanic
blacks, and 14% in non-Hispanic whites are obese [58]. Inter-
estingly, worse asthma control is uniformly associated with
increased body mass index in boys. Among girls, the direction
of this association varied with race/ethnicity [59]. Obese
Mexican American girls had greater odds of worse asthma
control compared with their normal-weight counterparts. In
contrast, obese African--American girls (overweight or obese)
had greater odds of having better asthma control compared
with their normal-weight counterparts [59].
Obese patients are less likely than the nonobese to achieve
asthma control with an ICS or an ICS combined with an
LABA [60]. ICSs might be less effective in overweight and
obese asthmatic subjects because in these patients inflamma-
tory state might have a systemic component rather than being
confined to the airways [61].
3.3 Environmental factors
It is widely accepted that exposure to ambient concentrations
of air pollutants can cause short-term exacerbations in those
who already have asthma [62]. Air pollution may contribute
to the higher prevalence of asthma, especially in some minor-
ity children exposed to higher levels of air pollution [63].
Obviously, effects of ethnicity might be confounded with
those effects associated with low socioeconomic status.
Lower-income, minority communities have higher exposures
to environmental pollutants because of the disproportionately
higher numbers of toxic waste dumps, major highways, bus
terminals, industry, and so forth located nearby [58]. In
USA, being a member of a racial/ethnic minority group
(non-Hispanic black 4.4%, Hispanic 5%, non-Hispanic
white 3.1%), being foreign born (5.1 vs 3.5% native born),
and speaking a language other than English at home (Spanish
5.1% vs English 3.3%) increases the probability of living close
to a major highway [64]. In a population of predominantly
African--American and Latino children living in the econom-
ically stressed city of Detroit, current levels of ambient air
pollution adversely affected children with asthma who were
corticosteroid dependent, a marker of the disease severity [65].
Recent exposure to NO2 and possibly O3 may reduce the
response to SABAs in producing bronchodilation in Mexican
children with asthma who were residing in a highly polluted
environment [66]. In any case, patients with severe asthma
might be the most likely to have respiratory symptoms with
exposure to air pollutants, despite treatment with steroids [67].
4. Adherence to therapy
Most obviously, if a person does not adhere to treatment,
symptoms may not be relieved or the disorder may not be
cured. Differences in adherence to therapy by race-ethnicity
are well described. External factors such as income, possession
of commercial health insurance, psychosocial stressors (e.g.,
residential crime rates) and characteristics of the facility where
care is provided can all affect the level of medication adher-
ence [68]. Internal factors, such as patients’ beliefs, mainly
belief in God’s control of health, knowledge and motivation,
may also influence adherence to asthma therapy [68].
It is likely that misunderstanding of the role of inhaled
anti-inflammatory medication is the main factor associated
with reduced adherence to its daily use [69]. However,
patient-dependent factors, such as cultural attitudes toward
treatments, disease treatment expectations and effects on the
Influence of ethnicity on response to asthma drugs
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quality of life, are also likely to play a significant role in shap-
ing patients’ approach to asthma management and their
acceptance of asthma and its impact.
A study carried out in Detroit, USA identified poorer ICS
adherence in African--American patients compared with white
patients even after adjusting for multiple socioeconomic vari-
ables [70]. In any case, African--American patients also had a
lower median household income and a higher index crime
rate in their area of residence and were more likely to live in
an inner-city location. In the Pharmacogenetics of Asthma
Medication in Children: Medication with Anti-inflammatory
Effects (PACMAN) cohort study, Dutch ethnicity was associ-
ated with higher ICS adherence rates [71]. Non-Dutch parents
had more often high concerns about their child’s medication
use, and were more often low educated.
5. Conclusion
Compared to their white counterparts, African--Americans
and Hispanics/Latinos suffering from asthma seem to be less
responsive to ICSs and LABAs when prescribed as part of
the general asthma guidelines. A variety of factors including
race/ethnicity, genetics, culture and environment give reason
for the lack of treatment efficacy in these groups.
6. Expert opinion
The published evidence clearly shows that our understanding
of whether and/or how ethnicity influences pharmacological
response to asthma therapeutics is still very scarce and almost
all the information available to us have been produced in
USA. Unfortunately, minority ethnic people are markedly
under-represented in research [72] and in any case, compara-
tive USA--European data reveal that minority ethnic people
are significantly more likely to be recruited into asthma trials
in the USA than in Europe [73] likely because the US National
Institute of Health’s (NIH) Revitalization Act 1993 dictates
that all NIH-funded clinical research must include people
from ethnic minority groups [74], whereas there is no similar
mandatory policy in the European Union.
This is a critical issue because an asthma treatment that
works well in a trial where all the participants are white
Europeans might not be suitable for other ethnic groups [72].
Therefore, health-care professionals might never use an
asthma treatment in all their patients irrespective of their
ethnicity and thus inadvertently increase ethnic health
inequality [72].
On the other hand, we must honestly admit that the
response to drug treatment in asthma is a complex trait and
is markedly variable even in patients with apparently similar
clinical features and, in any case, advances in defining
responders and nonresponders have not progressed signifi-
cantly since the sequencing of the human genome. Moreover,
asthma is regarded as a heterogeneous disorder with distinct
phenotypes and specific treatments for asthma are unlikely
to benefit all patients with asthma, but more likely target
specific phenotypes [75].
It is obvious that better phenotyping of patients and larger
sample sizes are absolutely required. Wechsler et al. [76]
stressed the importance of studying response to specific thera-
pies using race as a phenotype. We believe that this approach
is too simplistic and could lead to erroneous conclusions. For
example, in a study that replicated the Severe Asthma
Research Program (SARP) pediatric asthma clusters by using
a separate, large clinical trials network, early-onset/severe-
lung function and early-onset/comorbidity clusters were asso-
ciated with differential and limited response to therapy,
respectively, but there was no difference in race among
clusters [77].
Rather than consider race, we should think about the
genetic profile of the patient that we must treat. For instance,
there is much debate on the reduced response to LABAs in
African--American subjects harboring the Arg/Arg polymor-
phism at position 16 of the b-adrenoreceptor [22]. However,
we have already mentioned that this polymorphism is also
present in whites as well as in Chinese and Japanese and,
accordingly, it cannot be considered to be a peculiarity of a
specific race/ethnicity. In any case, the pharmacogenetic effect
of any individual variant is likely to be small [78]. Therefore,
given that multiple genes influence the bronchodilation
induced by b2-agonists, investigating the effects and potential
interaction of multiple genes is necessary. Each of these genes
may have a small but significant effect; thus, synergism may
exist between different genetic variants [78]. This makes the
possibility of a specific effect of race/ethnicity even weaker.
We completely agree with Ortega that, as our understand-
ing of the pharmacogenetics of asthma improves, it will then
be possible to create biomarkers panels designed for personal-
ized, precision approaches in asthma based on an individual’s
genetic profile [22]. In order to do so, it is time to move to a
more holistic integrative systems biology approach that
combines large-scale molecular profiling traits (e.g., transcrip-
tomic, proteomic, metabolomic traits) and genetic
variants [78].
The goal of all health-care professionals is to prescribe the
right drug for the right patient. Therefore, therapeutic options
must be tailored for each individual patient. This means that
clinicians must personalize the prescribed therapy. Personal-
ized medicine is based on individual characteristics such as
age, body mass index, race and local environment, with incor-
poration of predictive biomarkers including genetic profiles or
scores that combine several risk-associated genetic variants [79].
Obviously, the influence of ethnicity on pharmacological
response to asthma therapeutics is something that must be
considered. However, the mere focus on race/ethnicity runs
the risk of losing sight of the complexity of asthma and,
consequently, increasing ethnic health inequality in a true
unreasonable manner.
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